Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma
Next-generation sequencing has uncovered thousands of long noncoding RNAs (lncRNA). Many are reported to be aberrantly expressed in various cancers, including hepatocellular carcinoma (HCC), and play key roles in tumorigenesis. This review provides an in-depth discussion of the oncogenic mechanisms reported to be associated with deregulated HCC-associated lncRNAs. Transcriptional expression of lncRNAs in HCC is modulated through transcription factors, or epigenetically by aberrant histone acetylation or DNA methylation, and posttranscriptionally by lncRNA transcript stability modulated by miRNAs and RNA-binding proteins. Seventy-four deregulated lncRNAs have been identified in HCC, of which, 52 are upregulated. This review maps the oncogenic roles of these deregulated lncRNAs by integrating diverse datasets including clinicopathologic features, affected cancer phenotypes, associated miRNA and/or protein-interacting partners as well as modulated gene/protein expression. Notably, 63 deregulated lncRNAs are significantly associated with clinicopathologic features of HCC. Twenty-three deregulated lncRNAs associated with both tumor and metastatic clinical features were also tumorigenic and prometastatic in experimental models of HCC, and eight of these mapped to known cancer pathways. Fifty-two upregulated lncRNAs exhibit oncogenic properties and are associated with prominent hallmarks of cancer, whereas 22 downregulated lncRNAs have tumor-suppressive properties. Aberrantly expressed lncRNAs in HCC exert pleiotropic effects on miRNAs, mRNAs, and proteins. They affect multiple cancer phenotypes by altering miRNA and mRNA expression and stability, as well as through effects on protein expression, degradation, structure, or interactions with transcriptional regulators. Hence, these insights reveal novel lncRNAs as potential biomarkers and may enable the design of precision therapy for HCC.
Citations by journals
1
2
3
4
5
6
7
|
|
Frontiers in Oncology
|
Frontiers in Oncology
7 publications, 5.22%
|
Journal of Oncology
|
Journal of Oncology
5 publications, 3.73%
|
Aging
|
Aging
4 publications, 2.99%
|
Oncology Letters
|
Oncology Letters
3 publications, 2.24%
|
Cancers
|
Cancers
3 publications, 2.24%
|
Frontiers in Cell and Developmental Biology
|
Frontiers in Cell and Developmental Biology
3 publications, 2.24%
|
Biomedicine and Pharmacotherapy
|
Biomedicine and Pharmacotherapy
3 publications, 2.24%
|
Journal of Cellular and Molecular Medicine
|
Journal of Cellular and Molecular Medicine
3 publications, 2.24%
|
Bioengineered
|
Bioengineered
3 publications, 2.24%
|
Biomedicines
|
Biomedicines
2 publications, 1.49%
|
Molecular Medicine Reports
|
Molecular Medicine Reports
2 publications, 1.49%
|
World Journal of Gastroenterology
|
World Journal of Gastroenterology
2 publications, 1.49%
|
Frontiers in Genetics
|
Frontiers in Genetics
2 publications, 1.49%
|
BMC Cancer
|
BMC Cancer
2 publications, 1.49%
|
Journal of Experimental and Clinical Cancer Research
|
Journal of Experimental and Clinical Cancer Research
2 publications, 1.49%
|
Human Cell
|
Human Cell
2 publications, 1.49%
|
Cell Death Discovery
|
Cell Death Discovery
2 publications, 1.49%
|
Archives of Medical Research
|
Archives of Medical Research
2 publications, 1.49%
|
Pathology Research and Practice
|
Pathology Research and Practice
2 publications, 1.49%
|
Liver International
|
Liver International
2 publications, 1.49%
|
Journal of Hepatocellular Carcinoma
|
Journal of Hepatocellular Carcinoma
2 publications, 1.49%
|
Disease Markers
|
Disease Markers
2 publications, 1.49%
|
Heliyon
|
Heliyon
2 publications, 1.49%
|
Translational Cancer Research
|
Translational Cancer Research
2 publications, 1.49%
|
Journal of Cancer Research and Clinical Oncology
|
Journal of Cancer Research and Clinical Oncology
1 publication, 0.75%
|
Doklady Biochemistry and Biophysics
|
Doklady Biochemistry and Biophysics
1 publication, 0.75%
|
Epigenomics
|
Epigenomics
1 publication, 0.75%
|
Biomarkers in Medicine
|
Biomarkers in Medicine
1 publication, 0.75%
|
DNA and Cell Biology
|
DNA and Cell Biology
1 publication, 0.75%
|
1
2
3
4
5
6
7
|
Citations by publishers
5
10
15
20
25
|
|
Springer Nature
|
Springer Nature
22 publications, 16.42%
|
Elsevier
|
Elsevier
22 publications, 16.42%
|
Frontiers Media S.A.
|
Frontiers Media S.A.
18 publications, 13.43%
|
Hindawi Limited
|
Hindawi Limited
14 publications, 10.45%
|
Wiley
|
Wiley
13 publications, 9.7%
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
7 publications, 5.22%
|
Spandidos Publications
|
Spandidos Publications
7 publications, 5.22%
|
Impact Journals
|
Impact Journals
4 publications, 2.99%
|
Baishideng Publishing Group
|
Baishideng Publishing Group
4 publications, 2.99%
|
Taylor & Francis
|
Taylor & Francis
4 publications, 2.99%
|
AME Publishing Company
|
AME Publishing Company
4 publications, 2.99%
|
Future Medicine
|
Future Medicine
3 publications, 2.24%
|
Dove Medical Press
|
Dove Medical Press
3 publications, 2.24%
|
Pleiades Publishing
|
Pleiades Publishing
1 publication, 0.75%
|
Mary Ann Liebert
|
Mary Ann Liebert
1 publication, 0.75%
|
Public Library of Science (PLoS)
|
Public Library of Science (PLoS)
1 publication, 0.75%
|
Federation of American Societies for Experimental Biology (FASEB)
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.75%
|
Walter de Gruyter
|
Walter de Gruyter
1 publication, 0.75%
|
Oxford University Press
|
Oxford University Press
1 publication, 0.75%
|
Begell House
|
Begell House
1 publication, 0.75%
|
5
10
15
20
25
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.